• Ikena Oncology to Participate in September 2022 Investor Conferences

    Source: Nasdaq GlobeNewswire / 06 Sep 2022 07:30:00   America/New_York

    BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY.

    Management will be participating in investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference and at the Morgan Stanley 20th Annual Global Healthcare Conference, where Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, will also be conducting a fireside chat.

    Details are as follows:

    H.C. Wainwright 24th Annual Global Investment Conference
    Investor Meetings September 12-14, 2022

    Morgan Stanley 20th Annual Global Healthcare Conference
    Investor Meetings September 12-14, 2022
    Fireside Chat: Wednesday, September 14, 2022 at 11:45 a.m. ET, live and available for replay
    Webcast Link

    The presentation webcast will be available on the Company’s Events & Presentations page on their website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.

    About Ikena Oncology
    Ikena Oncology™ is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company’s lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway. Additional programs targeting the tumor microenvironment and immune signaling are in the clinic, including IK-175, an AHR antagonist, which is being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding: the timing and advancement of our targeted oncology programs, including the timing of updates; our expectations regarding the therapeutic benefit of our targeted oncology programs; our ability to efficiently discover and develop product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the implementation of our business model, and strategic plans for our business and product candidates. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of our targeted oncology programs; our expectations regarding the therapeutic benefit of our targeted oncology programs; expectations regarding our new executive officer; our ability to efficiently discover and develop product candidates; the implementation of our business model, and strategic plans for our business and product candidates, and other factors discussed in the “Risk Factors” section of Ikena’s Form 10-Q for the quarter ended June 30, 2022, which is on file with the SEC, as updated by any subsequent SEC filings. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

    Investor Contact:
    Rebecca Cohen
    Ikena Oncology
    rcohen@ikenaoncology.com

    Media Contact:
    Gwen Schanker
    LifeSci Communications
    gschanker@lifescicomms.com


    Primary Logo

Share on,